Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203033 | 0.91 | SLC5A1 (0.55) | CES2CES1SLC5A1SLC5A2ACKR3 | |
| SCHEMBL6203848 | 0.85 | DRD2 (0.51) | CES2CES1SLC5A1SLC5A2ACKR3 | |
| SCHEMBL6158144 | 0.78 | NPC1 (0.56) | SLC5A1SLC5A2RAB9ATAAR1FFAR1 | |
| SCHEMBL11847285 | 0.74 | CES2 (0.57) | CES2CES1ACKR3RAB9A | |
| SCHEMBL31661842 | 0.74 | CES2 (0.57) | CES2CES1ACKR3POLBMEN1 | |
| SCHEMBL959448 | 0.74 | CES2 (0.57) | CES2CES1ACKR3RAB9A | |
| SCHEMBL3527017 | 0.74 | CES2 (0.57) | CES2CES1ACKR3POLBMEN1 | |
| SCHEMBL6944180 | 0.74 | CES2 (0.57) | CES2CES1ACKR3 | |
| SCHEMBL19104747 | 0.73 | CES2 (0.61) | CES2CES1ACKR3RAB9A | |
| SCHEMBL31529633 | 0.73 | CES2 (0.61) | CES2CES1ACKR3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339694-B1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-09-21 | — | — | EP | disclosed |
| US-20020091147-A1 | SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | SYNTEX (U.S.A.) LLC | 2002-07-11 | — | — | US | disclosed |
| US-6417186-B1 | TREATING PAIN, URINARY TRACT INFECTIONS, INFLAMMATION, RESPIRATORY DISEASE STATES FROM ALLERGIES OR ASTHMA, EDEMA FORMATION OR HYPOTENSIVE VASCULAR DISEASES. | SYNTEX (U.S.A.) LLC | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091147-A1 | SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | PTGER1, FFAR1, BDKRB1 | CES2 2549/4885CES1 664/4885SLC5A1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.